‘Unlawful Marketing’ Doesn't Establish Dietary Ingredients' Use Before Drug Approval Or Study
Executive Summary
FDA explains thinking in a letter to Inner Mongolia Kingdomway Pharmaceutical after rejecting Chinese firm’s NDI notification for N-acetyl-L-cystein. Prior to its investigation as a drug, NMN wasn’t used in supplements available in US, “except unlawfully without an NDI notification.”
You may also be interested in...
US Dietary Ingredient ‘Preclusion’ Swings On Information Closed To Supplement Industry – CRN
Trade group contends FDA’s misuse of regulation prohibiting any substance studied or approved as a drug in US from being used as dietary ingredients undermines innovation in supplement industry and is detrimental to consumer choice and health.
US House Member Has Questions On FDA’s Policy On NMN, Also Asks For Public Hearing
Because FDA “suddenly changed its position and advised companies of its determination that NMN is excluded from the definition of a dietary supplement,” Rep. Jeff Duncan states, a public hearing “would be incredibly beneficial as the dietary supplement industry seeks clarity on the FDA’s actions.”
Tianeptine Rings Latest Unapproved Drug Alarm, Followed By Echo About Lack Of FDA Regulation
Tianeptine isn’t approved as drug in US nor allowed for use as dietary ingredient or food additive. FDA has warned multiple firms selling tianeptine-containing products and federal prosecutors recently announced guilty plea from man who sold the drug to consumers.